BCL2 and primary cutaneous T-cell non-Hodgkin lymphoma: For the histone deacetylase (HDAC) inhibitor Panobinostat [55] several resistance mechanisms have been observed such as overexpression of the anti-apoptotic protein Bcl-2 in cutaneous T-cell lymphoma patients [79].